
Jazz Pharmaceuticals Launches ALL Therapy Rylaze
The therapy is approved for both adults and children.
Jazz Pharmaceuticals has
Rylaze was licensed from Ligand Pharmaceuticals.
The only other FDA-approved drug for such patients with allergic reactions has been under global shortage since 2016. Jazz Pharmaceuticals’ Erwinaze (asparaginase erwinia chrysanthemi) has experienced supply and manufacturing issues from the owner and manufacturer of the product, Porton Biopharma Limited. Jazz Pharmaceuticals’
In May 2021, the FDA had authorized Porton Biopharma and its distributor Clinigen to import Erwinase (crisantaspase) into the United States and
Jazz licensed Rylaze from Ligand Pharmaceuticals, which received a $2 million payment when the FDA accepted the BLA for review and is entitled to receive a $5 million payment upon the first commercial sale following launch.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.